A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases.

Trial Profile

A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2011

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jun 2011 Actual initiation date changed from Sep 2004 to Oct 2004 as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Actual completion date identified as Oct 2007, as reported by ClinicalTrials.gov
    • 26 Jul 2007 The expected completion date for this trial is now 1 Apr 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top